| Document Date: 2014-02-24 11:18:11
Open Document File Size: 290,35 KBShare Result on Facebook
City San Francisco / Winnipeg / / Company Theravance / Astellas Pharma Canada Inc. / Merck Canada / MRSA / Bayer Canada / Abbott Laboratories / Pfizer Canada Inc. / / Continent North America / / Country Canada / / / Facility Health Sciences Centre / CANWARD hospital / West Ontario Quebec Maritimes Hospital / University of Manitoba2 / / IndustryTerm chromogenic media / healthcare / / MedicalCondition pneumonia / bacteremia / disease / epidemic / S. aureus / infection / soft tissue infections / infections / sepsis / / Organization Health Sciences Centre / University of Manitoba2 / FDA / / Person A. ONIO / Kim Nichol / / / Position Fisher / D.J. / / Product levofloxacin / cefazolin / trimethoprim / linezolid / cefoxitin / clarithromycin / ciprofloxacin / sulfamethoxazole / / ProvinceOrState Quebec / Manitoba / California / Ontario / / PublishedMedium Antimicrobial Agents and Chemotherapy / / Region West Ontario / / Technology Chemotherapy / genotype / /
SocialTag |
Continuing Evolution of USA300 (CMRSA10) Community-Associated Methicillin-Resistant Staphylococcus aureus (CA-MRSA) in Canadian Hospitals from[removed]C2[removed]